Critical Analysis and Patent Landscape for US 9,474,688 (Delamination-Resistant Pharmaceutical Glass Containers)

US 9,474,688 is directed to a pharmaceutical container that prevents delamination by using a specific boron-free glass composition paired with a pharmaceutical payload broadly covering many drug classes, including specified biologics (mAbs, enzymes, antibodies) and small molecules. The claims are dominated by tight compositional boundaries for SiO₂, MgO/CaO, Na₂O (alkali oxide), Al₂O₃, and optional additions (e.g., SnO₂), plus functional framing (“delamination resistant” and “delamination factor of 1”).

The patent’s enforceability and value hinge on three technical questions: (i) whether competitors can design around the compositional ratios and exclusions, (ii) whether the “delamination factor” and “delamination resistant” terms are sufficiently supported to establish a clear infringement standard, and (iii) how far claim scope extends across container formats and across a very long enumerated list of pharmaceutical agents.

What does US 9,474,688 actually claim?

Core claim structure

The independent claims (1-3) each require a container that has:

A pharmaceutical composition stored inside.
A glass composition with the following key attributes:
- Boron-free: “free of boron and compounds of boron”
- High silica: SiO₂ at a threshold or range
- Alkaline earth oxides: includes MgO and CaO with CaO limited and CaO/(CaO+MgO) bounded
- Alkali oxide: specified as Na₂O at defined levels; Y:X ratio bounded
- Aluminum oxide: Al₂O₃ at defined levels (with X used as Al₂O₃ in mol.%)
A very broad set of pharmaceutical payloads, enumerated as a long list (antidiabetics, mAbs, antivirals, vaccines, immunoglobulins, imaging agents, etc.).

Claim 4 adds container formats; claims 5-6 add delamination-resistance framing; claims 7-39 further constrain payload selection and composition sub-ranges.

Which glass parameters control scope and design-around feasibility?

1) Boron-free restriction (hard constraint)

All independent claims require:

No boron and no boron compounds

This is a meaningful carve-out in a glass landscape where borate glasses can be used for wetting, chemical durability tuning, and processing. The boron-free requirement forces competitors away from borosilicate or borate-containing formulations.

Design-around: Use non-boron glass already in use (e.g., aluminosilicates, phosphate-free variants), but still satisfy other ratio constraints. If competitors already operate in this space, this restriction is less differentiating; if they rely on boron-containing chemistries, it is a direct barrier.

2) Silica window: high SiO₂ (but not ultra-tight in all claims)

Claim 1: SiO₂ > 74 mol.%
Claim 2 and claim 3: SiO₂ from 74 to 78 mol.%

Design-around: Competing glass compositions with SiO₂ at 78-85 mol.% can avoid claims 2 and 3 but may still fall under claim 1 (since claim 1 only needs >74 mol.%). So the silica window is not a strong design-around lever unless competitors move below/at 74 mol.% (unlikely for durability-driven formulations) or adopt higher silica while keeping other elements outside the claim 2/3 ranges and outside X/Y constraints.

3) Alkaline earth system: MgO/CaO with a CaO ceiling and a CaO:MgO ratio cap

Key constraints:

CaO amount:
- Claim 1: 0.1 to 1.0 mol.% (CaO)
- Claim 2: also CaO 0.1 to 1.0 mol.% via same limitation
- Claim 3: same 0.1 to 1.0 mol.% (explicit)
CaO/(CaO+MgO) ≤ 0.5 (all independent claims)

Dependent claims introduce tighter ceilings:

Claim 19: CaO/(CaO+MgO) ≤ 0.3

Design-around: The most direct “knob” is the CaO fraction relative to MgO. If competitors can shift the alkaline earth balance such that CaO/(CaO+MgO) exceeds 0.5, they move out of the independent claims. If they keep CaO inside 0.1 to 1.0 but increase CaO relative to MgO, they can also exit.

However, CaO/MgO ratios are typically balanced to achieve thermal expansion matching, interface strength, and chemical durability. Shifting these ratios without creating other failure modes (e.g., stress cracking, corrosion, or delamination under thermal cycling) is the practical challenge.

4) Alkali system: Na₂O high and Y:X > 1

Claim 1: Y is alkali oxide comprising:
- Na₂O > 8 mol.%
Claim 2:
- Na₂O 9 to 15 mol.%
- Y:X > 1
Claim 3:
- Na₂O 0.01 to 1.0 mol.% appears as written in the claim text you provided, paired with “Y:X > 1.” That combination is internally unusual because if X (Al₂O₃) is 2 to 10 mol.%, then Y:X > 1 with Na₂O below 1 mol.% would require X < 1 mol.%, contradicting X constraints in independent claims as provided. The claim text as supplied is the controlling input here, but the inconsistency materially impacts interpretive outcomes and enforcement clarity.

Dependent claim 34 further constrains:

Na₂O 9 to 13 mol.% (claim 3 dependent in your list, but the numbering you provided maps to claim 3 limitations)

Design-around: Na₂O content is a strong lever. A formulation that keeps Na₂O below the “greater than about 8 mol.%” threshold avoids claim 1, but may be hard to reconcile with the claimed “delamination resistant” outcome. Infringement is also ratio-driven: even if Na₂O is within range, Y:X must satisfy >1 (and often <=2 in dependent claims).

5) Al₂O₃ “X” requirement (2 to 10 mol.% with ratio tuning)

Claim 1: X mol.% Al₂O₃, where X is 2 to 10 mol.%
Dependent claim set:
- Claim 13: adds X with Y:X > 1
- Claim 14: Y:X <= 2
- Claim 17: Y:X 1.3 to 2
- Claim 18: X 5 to 7 mol.%
- Claim 15 reiterates X 2 to 10

Design-around: Competitors can avoid by moving Al₂O₃ below 2 mol.% or above 10 mol.% while keeping the other elements. Another pathway is shifting Y:X so that it falls at or below 1 (or above the upper bound if using dependent claim constraints).

6) Optional tin: SnO₂

Claim 20: “further comprising SnO₂”

Design-around: If tin is not present, claim 20 is avoided, but independent claims likely still cover the absence of SnO₂ unless tin is required by the asserted claims. Tin typically is used as a refining/clarifying agent or to tune durability; its inclusion can create narrower sub-scope.

How broad is the “pharmaceutical composition” coverage?

Payload enumeration

Claims 1-3 recite that the pharmaceutical composition comprises one selected from a list that includes:

antidiabetics (multiple insulins and GLP-1 agents)
anti-neoplastic mAbs and antibody-drug conjugates (e.g., trastuzumab emtansine, brentuximab vedotin, etc.)
antirheumatics (multiple biologics)
antivirals/antibacterial (e.g., ceftolozane/tazobactam, ceftaroline)
cytostatics and gene therapy style agents (e.g., velimogene aliplasmid, ganetespib, etc.)
vaccines across multiple categories
immunosuppressants
anti-fibrinolytics (factor VIII/IX variants)
eye preparations (aflibercept, ranibizumab, ocriplasmin)
MS therapeutics and neurologic therapeutics (alemtuzumab, ocrelizumab, interferon beta variants)
bone calcium regulators and anti-coagulants
anti-psychotic (aripiprazole)
imaging agents (minretumomab)
immune stimulants (pegfilgrastim)
immune globulin (listed)

Claim 7 is a dependency that tightly enumerates drugs under each category; it functions as both:

a scope amplifier (because it lists many specific actives), and
an evidentiary pressure point (because it ties the claim’s coverage to the specified “selected from” lists if a court construes this as requiring exact match).

pH and buffer limitations (claims 8-10)

Claims add constraints on excipients/solution state:

Claim 8: citrate buffer or phosphate buffer
Claim 9: buffer variants include sodium citrate, SSC, monosodium phosphate, disodium phosphate
Claim 10: solution pH between about 7 and about 11

These constraints narrow enforceability for containers used with other buffers (histidine, acetate, TRIS, etc.) or different pH windows, if those claim dependencies are asserted.

What does “delamination resistant” mean in an enforceable way?

The claim text you provided includes:

Claim 5: container is delamination resistant
Claim 6: container has a “delamination factor of 1”

This indicates the patent intends an objective test metric. For infringement, a court typically needs:

a determinable method to measure the delamination factor; and
clear boundaries for “1” versus “greater than 1” (or similar).

Landscape impact: If “delamination factor” is defined tightly in the specification and measured under standardized stress conditions, the patent can act as a measurable differentiator and supports validity/infringement arguments. If the factor is not robustly defined, it can increase litigation risk and weaken the certainty of enforceable boundaries.

Key dependent claim features that narrow or create litigation leverage

Composition specificity overlays (claims 2-3)

Claim 2 tightens SiO₂ to 74-78 and Na₂O to 9-15, with Y:X > 1.
Claim 3 changes Na₂O and K₂O language:
- Claim 26: alkali oxide further comprises K₂O 0.01 to 1.0 mol.%
- Claim 3 in your text also includes Na₂O 0.01 to 1.0 mol.% which conflicts with the independent constraints as written.

Practical effect: These layered ranges suggest the patentee mapped a “formulation region” where delamination resistance is improved. Competitors outside those ranges can credibly design around, but only if the delamination performance correlates with the chemistry rather than with the container manufacturing process (temper, thermal treatment, surface treatments).

Phosphorus exclusions

Claim 12: glass free from phosphorous and compounds of phosphorous
Claim 31 repeats for claim 3 dependency

Design-around: Competitors using phosphorus-containing glass would exit the claim set.

Tight ratio constraints for Y:X

Claims 17, 21-22, 28-29, 14-15 type constraints:
- Y:X sometimes bounded up to 2
- sometimes bounded 1.3 to 2.0

These ratios can become the primary infringement battleground because they are hard to infer without composition analysis.

CaO/MgO ratio tightening

Claim 19: CaO/(CaO+MgO) ≤ 0.3

This is likely a performance-optimized sub-range. It also creates a measurable line for design-around: if competitors use CaO/MgO such that CaO/(CaO+MgO) is between 0.3 and 0.5, they could avoid narrower dependent claim scopes while still potentially touching independent claim 1.

X sub-range narrowing (claims 18 and 27)

Claim 18: X = 5-7 mol.% Al₂O₃
Claim 27: X = 5-7 mol.% Al₂O₃

If enforced via these dependencies, the scope shrinks. But if asserted via independent claims, those sub-ranges may not matter.

Container format flexibility

Claim 4: vial, cartridge, syringe, ampoule, bottle, flask, vacutainer

This is broad across product form factors used in injectables and diagnostics.

Where does the enforceability risk concentrate?

1) Overbreadth across pharmaceutical payloads

The claims cover “one of” a large set of agents, many of which are not inherently compatible with the same storage conditions. The claim language frames “delamination resistant container” but also requires that the stored pharmaceutical composition comprises the listed agent.

Risk point: If competitors argue that delamination resistance is achieved by the container glass composition independent of which drug is inside, then the payload list may be treated as non-essential and could be attacked in validity arguments (depending on claim construction and how the payload list is interpreted). In practice, patents that list specific actives often survive if the specification supports that the container is compatible across a range of payload chemistries and the actives are representative.

2) Dependency on pH/buffer and exclusions

If the asserted claims include buffer/pH dependencies (claims 8-10), infringement requires matching the formulation environment, not just the glass composition.

If asserted only via independent claims (claims 1-3), the payload list becomes the gating element. That can be easier to prove if a product is known to contain those drugs with standard buffers, but can also create evidentiary burdens if drug formulations differ across markets.

3) Internal inconsistency risk in claim text you provided

As noted, the Na₂O levels in claim 3 as provided conflict with the Y:X > 1 requirement if X is constrained to 2-10 mol.%. That creates a potential interpretive problem: courts may construe “Y:X” using the defined variables, or they may rely on specification definitions. In enforcement strategy, this is a litigation risk.

4) Manufacturing-process confounding

Delamination can be affected by:

thermal histories,
surface finishing,
coatings,
annealing,
dimensional stresses,
and container design (e.g., thickness gradient).

If the patent’s “delamination factor of 1” is achieved via specific manufacturing conditions in addition to the glass chemistry, competitors can attempt to replicate the glass composition but use different processes to achieve higher delamination risk (design-around by process rather than composition). The claims, as provided, are composition-based, which limits process-based defenses if the glass chemistry is met.

How does this sit in the broader patent landscape?

Competitive overlap zones

US 9,474,688 targets a classic pharmaceutical packaging failure mode: glass delamination, especially in the context of:

thermal cycling,
chemical leaching and hydration layers,
interface failures under stress.

The likely landscape overlap includes:

borosilicate and aluminosilicate glass families used for injectables,
boron-free specialty glasses used for chemical durability,
multilayer or surface-engineered glass approaches,
container coatings and surface treatments that reduce delamination without changing bulk glass compositions.

Because US 9,474,688 is composition-heavy (SiO₂, Na₂O, CaO/MgO, Al₂O₃, boron exclusion), its defensibility is strongest where competitors either:

rely on boron-containing glasses (blocked by the boron-free limitation), or
rely on alkaline earth/alkali ratios outside the constrained region.

Likely design-around pathways

Move Na₂O out of range (below “about 8 mol.%” or outside 9-15 mol.% for claim 2)
Shift CaO/(CaO+MgO) above the cap (e.g., >0.5) to exit independent claims
Change Al₂O₃ content outside 2-10 mol.%
Introduce phosphorus (if phosphorus-containing glasses can achieve performance)
Use a different glass base (still boron-free but with different alkali systems, e.g., K-dominant rather than Na-dominant, though claim 1 is tied to Na₂O being the alkali oxide component)
Change container manufacturing to increase delamination despite matching bulk chemistry

Freedom-to-operate implication

For a competitor considering a new glass formulation for vials/syringes:

a single compositional mismatch on the ratio or exclusion can neutralize claim 1/2/3 coverage; and
if they rely on citrate/phosphate buffer formulations, the pH and buffer dependencies can narrow the set of potentially infringing commercial products.

Claim-by-claim leverage map (what to watch in prosecution or litigation)

Claim	Main differentiator	Litigation lever
1	SiO₂ >74 mol.%, CaO 0.1-1.0, CaO/(CaO+MgO) ≤0.5, Na₂O >8 mol.%, boron-free, X=Al₂O₃ 2-10	Broad independent basis; hard to design around if Na-rich and Ca-limited boron-free glasses are used
2	SiO₂ 74-78, CaO/(CaO+MgO) ≤0.5, X=Al₂O₃ 2-10, Na₂O 9-15, Y:X>1	Narrower glass window; ratio boundaries become main infringement test
3	Boron-free; SiO₂ 74-78; CaO/(CaO+MgO) ≤0.5; X=Al₂O₃ 2-10; K₂O optional via dependent; Na₂O constraint as written	Potential internal inconsistency risk as provided; useful for interpretive arguments
4	container forms	Broadens product coverage; weaker on novelty
5-6	delamination resistant; delamination factor of 1	Depends on test method and definition in spec
7	payload selection list (very extensive)	Evidentiary burden; scope amplifier; may be contested for enablement/utility if unsupported across actives
8-10	citrate/phosphate buffers; pH 7-11	narrows to specific formulation environments
12,31	phosphorous exclusion	design-around lever
13-18,17,19	tighter ratio and subranges	enables narrower infringement and validity arguments
20	optional SnO₂	may create a supplemental niche sub-scope
21-23,24-27,28-30	tighter ratio and alkali/alkaline earth subranges	compositional carve-outs for design-around
32-35	Na₂O constraints and X=5-7	helps specify competitor windows

Where is the strongest innovation signal versus where scope may be vulnerable?

Strongest innovation signal

A boron-free high-silica, Na-rich aluminosilicate glass with bounded CaO relative to MgO and bounded Y:X ratio appears tailored to a specific physical failure mode (delamination).
The “delamination factor of 1” suggests the patent was built around measurable performance rather than general glass durability.

Scope vulnerability

The “pharmaceutical composition comprises one of” list is extremely broad across drug classes. If the specification does not demonstrate that delamination performance is independent of drug class (or that delamination resistance is achieved across the listed formulations), challengers may argue the list is not functionally tied to the invention.
Any internal variable mismatch in the claim text (notably claim 3 Na₂O versus Y:X) can be used to argue for narrow or inconsistent interpretation, affecting enforcement certainty.

Key Takeaways

US 9,474,688 is composition-driven: enforceability depends mainly on meeting SiO₂, Na₂O, Al₂O₃ (X), and CaO/MgO ratio constraints, plus boron-free and optionally phosphorous-free glass.
The most practical design-around lever is shifting CaO/(CaO+MgO) above the cap or moving Na₂O and Y:X ratios outside the defined windows.
The patent’s payload coverage is broad because it enumerates many drug actives, but dependencies on buffer type and pH range (7-11) can narrow infringement to specific formulation environments.
“Delamination factor of 1” is a critical enforceability hook; its value in litigation depends on whether the measurement method is defined and reproducible in the specification.
Dependent claim sub-ranges (X=5-7, Y:X 1.3-2.0, CaO/(CaO+MgO) ≤0.3) create additional carve-outs and can support partial invalidation or narrow infringement theories.

FAQs

What single restriction most reduces design-around options?
The glass is required to be “free of boron and compounds of boron,” which blocks borate/borsilicate glass families used in some pharmaceutical packaging.
Which ratio is likely the key infringement boundary?
CaO/(CaO+MgO) ≤ 0.5 in the independent claims, and ≤0.3 in a dependent claim, is likely to be the most defensible compositional delimiter.
Does the patent cover all pharmaceutical containers?
It covers multiple formats (vial, cartridge, syringe, ampoule, bottle, flask, vacutainer) but only when the container uses the claimed glass composition and stores one of the listed pharmaceutical agents (and, if asserted, matching buffer/pH dependencies).
Is the pharmaceutical payload a minor detail or a scope driver?
It is a scope driver because independent claims require that the stored pharmaceutical composition comprises one of the enumerated agents, with additional narrowing through buffer/pH dependencies in dependent claims.
What evidence typically matters most for infringement?
Glass composition analysis (molar percentages and ratios), boron/phosphorus absence testing, and matching to the claimed payload formulations (including buffer type and pH where those dependencies are asserted).

References

US 9,474,688 patent claims and claim text as provided by the user.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982	⤷ Start Trial	2032-10-25
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015	⤷ Start Trial	2032-10-25
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998	⤷ Start Trial	2032-10-25
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	March 31, 1994	⤷ Start Trial	2032-10-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Summary for Patent: 9,474,688